IBRX vs PATH
Immunitybio Inc (IBRX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported IBRX revenue for 2024-12-31 was $14.7M. Net income was -$413.6M. Revenue was up 2270.6% from 2023-12-31 to 2024-12-31. IBRX currently screens at market cap $7.88B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
IBRX currently screens at market cap $7.88B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the IBRX and PATH stock pages for the full models.
Not investment advice.